Non-Hodgkin lymphoma secondary to cancer chemotherapy

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 3, 2007, Pages 377-380

  Krishnan, Biju ^a   Morgan, Gareth J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL CYCLE ARREST; CONFERENCE PAPER; DISEASE DURATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MORTALITY; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; RISK FACTORS;

EID: 34047264802     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-1069     Document Type: Conference Paper

References (24)

1. Wolniak KL, Shinall SM, Waldschmidt TJ. The germinal center response. Crit Rev Immunol 2004;24:39-65.
2. Moertel CG, Hagedorn AB. Leukemia or lymphoma and coexistent primary malignant lesions: a review of the literature and a study of 120 cases. Blood 1957;12:788-803.
3. Arseneau JC, Sponzo RW, Levin DL, et al. Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med 1972;287:1119-22.
4. Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS. Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med 1979;300:452-8.
5. Rosner F, Grunwald HW. Non-Hodgkin's lymphoma after treatment of Hodgkin's disease. Arch Intern Med 1983;143:2335-9.
6. Bennett MH, MacLennan KA, Vaughan HG, Vaughan HB. Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation. Ann Oncol 1991;2 Suppl 2:83-92.
7. Shimizu Y, Kato H, Schull WJ. Studies of the mortality of A-bomb survivors. 9. Mortality, 1950-1985: part 2. Cancer mortality based on the recently revised doses (DS86). Radiat Res 1990;121:120-41.
8. Darby SC, Doll R, Gill SK, Smith PG. Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis. Br J Cancer 1987;55:179-90.
9. Mauch PM, Kalish LA, Marcus KC, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996;87:3625-32.
10. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood 1995;86:3542-52.
11. Drablos F, Feyzi E, Aas PA, et al. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair (Amst) 2004;3:1389-407.
12. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68.
13. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983;51:2293-300.
14. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996;184:1495-505.
15. Foss AA, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin's disease: the influence of treatment, age and follow-up time. Ann Oncol 2002;13:1786-91.
16. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997;89:1429-39.
17. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988;318:76-81.
18. Kaldor JM, Day NE, Band P, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987;39:571-85.
19. Hooning MJ, Aleman BM, van Rosmalen AJ, Kuenen MA, Klijn JG, van Leeuwen FE. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006;64:1081-91.
20. Henry-Amar M. Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease. Ann Oncol 1992;3 Suppl 4:117-28.
21. Van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312-25.
22. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18:498-509.
23. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-29.
24. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-51.